Upside case
Bull case
—
The bull case requires both strong earnings delivery and the market pricing DBVT more generously than it does today.
Analysis OverviewBuyUpdated May 1, 2026
DBV Technologies S.A. (DBVT) Stock Analysis
Wall Street verdict, consensus price target, and analyst rating breakdown — everything needed to frame the risk/reward at today's price.
Analyst consensus
Buy
Covering
15
analysts
10 bullish · 1 bearish · 15 covering DBVT
Strong Buy
0
Buy
10
Hold
4
Sell
1
Strong Sell
0
Consensus Target
$46
+137.7% vs today
Scenario Range
— – —
Model bear to bull value window
Coverage
15
Published analyst ratings
Valuation Context
—
Forward P/E · Market cap $1669.52T
DBVT price targets
Three scenarios for where DBVT stock could go
Current
~$19
Confidence
29 / 100
Updated
May 1, 2026
Market caseClosest to today
Base case
—
The base case reflects analyst consensus expectations — steady delivery without requiring a major catalyst or re-rating.
Stress case
Bear case
—
The bear case reflects a scenario where earnings shortfalls or multiple compression combine to materially reduce the stock from its current level.
Not financial advice. Model confidence reflects internal scenario assumptions, not a guarantee of returns. Past performance does not predict future results.
DBV Technologies S.A.
DBVT · NASDAQHealthcareBiotechnologyDecember year-end
DBV Technologies is a clinical-stage biopharmaceutical company developing epicutaneous immunotherapy patches for food allergies. It aims to generate revenue through future sales of its lead product Viaskin Peanut — which has completed Phase III trials — and other pipeline candidates like Viaskin Milk and Viaskin Egg. The company's key advantage is its proprietary Viaskin patch technology platform, which delivers allergens through the skin rather than injections or oral routes — potentially offering a safer, more convenient treatment option.
Market Cap
$1669.52T
Revenue TTM
$0
Net Income TTM
-$168M
DBVT Revenue and Earnings Performance
Quarterly beat-or-miss track record against analyst estimates, plus forward revenue and EPS outlook for the next two fiscal years.
EPS Beat Rate
75%Exceptional
12 quarters tracked
Revenue Beat Rate
58%Exceptional
vs consensus estimates
Avg EPS Surprise
-33.3%
above Street consensus
Beat / Miss Record
BeatMissLeft = EPS · Right = Revenue
Q4 2025
Q1 2026
Q1 2026
Q2 2026
Last 4 Quarters
EPS beats: 4 of 4Q4 2025
EPS
$-1.20/$-1.45
Revenue
$3M/$1M
Q1 2026
EPS
$-1.15/$-1.30
Revenue
$574600/$1M
Q1 2026
EPS
$-1.15/$-1.30
Revenue
$574600/$1M
Q2 2026
EPS
$-0.13/$-0.13
Revenue
$1M/$1M
| Quarter | EPS (Actual / Est) | EPS Surprise | Revenue (Actual / Est) | Rev Surprise |
|---|---|---|---|---|
| Q4 2025 | $-1.20/$-1.45 | +17.2% | $3M/$1M | +204.5% |
| Q1 2026 | $-1.15/$-1.30 | +11.5% | $574600/$1M | -60.5% |
| Q1 2026 | $-1.15/$-1.30 | +11.5% | $574600/$1M | -60.5% |
| Q2 2026 | $-0.13/$-0.13 | +0.9% | $1M/$1M | -4.9% |
FY1–FY2 Estimates
Revenue Outlook
FY1
$1M
+115.0% YoY
FY2
$18M
+1577.6% YoY
EPS Outlook
FY1
$-0.14
+97.8% YoY
FY2
$-0.05
+67.6% YoY
Trailing FCF (TTM)-$151M
Next Earnings
—
Expected EPS
—
Expected Revenue
—
DBVT beat EPS estimates in 4 of 4 tracked quarters. A perfect track record raises the bar for the upcoming report.
DBVT Valuation Snapshot
Current multiples compared to the S&P 500, the company's sector, and its own five-year average.
Relative Value Signal
Relative Valuation
Benchmark comparison across market, sector, and history below.
Deep DiscountFair ValueVery Expensive
vs S&P 500 Trailing P/E
DBVT
-0.7x
vs
S&P 500
25.1x
103% discount
vs Healthcare Trailing P/E
DBVT
-0.7x
vs
Healthcare
22.2x
103% discount
vs DBVT 5Y Avg P/E
Today
-0.7x
vs
5Y Average
—
Benchmark unavailable
Forward PE
—
S&P 500
19.1x
—
Healthcare
18.8x
—
5Y Avg
—
—
Trailing PE
-0.7x
S&P 500
25.1x
-103%
Healthcare
22.2x
-103%
5Y Avg
—
—
PEG Ratio
—
S&P 500
1.72x
—
Healthcare
1.53x
—
5Y Avg
—
—
EV/EBITDA
—
S&P 500
15.2x
—
Healthcare
14.0x
—
5Y Avg
—
—
Price/FCF
—
S&P 500
21.1x
—
Healthcare
18.6x
—
5Y Avg
—
—
Price/Sales
—
S&P 500
3.1x
—
Healthcare
2.8x
—
5Y Avg
30.6x
—
Dividend Yield
—
S&P 500
1.87%
—
Healthcare
1.42%
—
5Y Avg
—
—
| Metric | DBVT | S&P 500 | Healthcare | 5Y Avg DBVT |
|---|---|---|---|---|
| Forward PE | — | 19.1x | 18.8x | — |
| Trailing PE | -0.7x | 25.1x-103% | 22.2x-103% | — |
| PEG Ratio | — | 1.72x | 1.53x | — |
| EV/EBITDA | — | 15.2x | 14.0x | — |
| Price/FCF | — | 21.1x | 18.6x | — |
| Price/Sales | — | 3.1x | 2.8x | 30.6x |
| Dividend Yield | — | 1.87% | 1.42% | — |
DBVT trades above S&P 500 benchmarks on 0 of 1 measured multiples — appears modestly priced relative to the S&P 500 on most measures.
Forward P/E and PEG reflect analyst consensus estimates. Historical averages use trailing ratios where forward data is unavailable.S&P 500 and sector benchmarks both use trailing median P/E — similar readings indicate the broader index and sector are priced alike.
Open valuation toolDBVT Financial Health
Verdict
Stressed
Key financial metrics for DBVT are shown below.
Cash Engine
Revenue, margins, and cash generation
Revenue (TTM)
Trailing-twelve-month sales base
$0
Revenue Growth
TTM vs prior year
-100.0%
Gross Margin
Gross profit as a share of revenue
—
Operating Margin
Operating income divided by revenue
—
Net Margin
Net income divided by revenue
—
EPS (TTM)
Diluted earnings per share, trailing twelve months
$0.00
Free Cash Flow (TTM)
Cash generation after capex
-$151M
FCF Margin
FCF as share of revenue — the primary cash quality signal
—
Capital Quality
ROIC, leverage, and debt serviceability
ROIC
Return on invested capital — primary competitive quality signal
—
ROA
Return on assets, trailing twelve months
-89.0%
Cash & Equivalents
Liquid assets on the balance sheet
$194M
Net Cash
Cash exceeds total debt — no net leverage
$172M
Debt Serviceability
Net debt as a multiple of annual free cash flow
Net cash ✓
ROE
Return on equity, trailing twelve months
-130.2%
Shareholder Returns
How capital is returned to owners
Total shareholder yield
0.0%
Dividend
—
Buyback
0.0%
Share Repurchases
Trailing buyback outflow — dollar magnitude of capital returned
$0
Dividend / Share
Annualized trailing dividend per share
—
Payout Ratio
Share of earnings distributed as dividends
—
Shares Outstanding
Current diluted share count
85.66T
All figures from the trailing twelve months. ROIC uses invested capital (equity + net debt).
Open full ratios pageDBVT Stock Risk Factors
Key factors that could pressure the stock price, compress the multiple, or weigh on future results.
Based on the latest company results, valuation, and market data
Medium
Valuation de-rating
DBVT trades at -0.7x trailing earnings versus 25.1x for the S&P 500 and 22.2x for its sector. If earnings delivery or sentiment slips, the stock could re-rate lower and move closer to the bear case target of —.
Medium
Estimate execution
The next fiscal year requires Street estimates of $1M in revenue (115.0% growth) and $-0.14 in EPS. Missing those operating targets would undermine the premium multiple investors are paying today.
Lower
Capital return support
Part of the per-share support comes from capital returns, backed by -$151M in trailing free cash flow, a 0.0% buyback yield. If cash generation softens, the EPS lift and downside cushion from repurchases can narrow.
These are risk mechanisms, not predictions. The key question is which would force a cut to earnings estimates or a lower multiple than the market currently prices in.
Why DBVT Stock Could Outperform
Structural drivers behind the upside case and why the stock could outperform over the next 12 months.
Based on recent company results and analyst estimates
High-margin cash engine
DBV Technologies S.A. already operates from a position of scale, with — gross margin, — operating margin, and -$151M in trailing free cash flow. That combination gives management room to keep funding product investment without relying on outside capital.
Multiple growth levers remain
DBV Technologies S.A. still has room to compound if management converts its existing scale into steadier revenue growth and margin discipline. The bull case does not require perfection; it requires the core business to keep translating operating strength into higher per-share earnings.
Upside and capital returns align
Consensus still points to $46, or 137.7% upside, while the modeled bull target reaches —. If $1M in forward revenue and $-0.14 in EPS are delivered, ongoing shareholder returns running at 0.0% can amplify the equity upside.
A real bull case compounds — each driver matters most when it strengthens margins, supports capital returns, and keeps the company above the market's minimum growth bar simultaneously.
DBVT Stock Price Performance
52-week range context and price returns across multiple time horizons. Dividend contribution is shown separately in the Capital Return section.
Current Price
$19.49
52W Range Position
64%
52-Week Range
Current price plotted between the 52-week low and high.
52-Week Low
$7.53
+158.8% from the low
52-Week High
$26.18
-25.6% from the high
1 Month
-4.27%
3 Month
-9.18%
YTD
+2.3%
1 Year
+110.7%
3Y CAGR
+5.7%
5Y CAGR
-21.2%
10Y CAGR
-18.5%
Range context matters because valuation compression and earnings misses rarely hit from the same starting point. A stock already far below its high can still fall, but it is no longer carrying the same embedded optimism as one pressing a fresh peak.
DBVT vs Peers
Valuation, growth, and margin comparison against the closest publicly traded peers for this company.
Peer Set
Accurate peer set
Forward PE
—
vs 6.8x median
Peer median unavailable
Revenue Growth
+115.0%
vs +2.6% median
+4283% above peer median
Net Margin
—
vs 16.4% median
Peer median unavailable
| Company | Mkt Cap | Fwd PE | Rev Grw | Margin | Rating | Upside |
|---|---|---|---|---|---|---|
DBV DBVT DBV Technologies S.A. | $1669.52T | — | +115.0% | — | Buy | +137.7% |
ALK ALKS Alkermes plc | $6.1B | — | +7.1% | 16.4% | Buy | +21.4% |
PRG PRGO Perrigo Company plc | $1.6B | 5.5x | -1.9% | -33.5% | Hold | +71.8% |
SLR SLRX Salarius Pharmaceuticals, Inc. | $697790 | — | — | — | — | — |
SNG SNGX Soligenix, Inc. | $3M | — | -100.0% | — | — | — |
HAL HALO Halozyme Therapeutics, Inc. | $7.8B | 8.2x | +33.7% | 22.7% | Buy | +18.9% |
This peer comparison reflects companies with similar business models, product lines, or market positioning, supplemented by industry grouping when direct matches are limited.
FAQ
7 questionsDBVT Investor Questions
Common questions answered from live analyst data and company financials.
01Is DBV Technologies S.A. (DBVT) stock a buy or sell in 2026?
DBV Technologies S.A. (DBVT) is rated Buy by Wall Street analysts as of 2026. Of 15 analysts covering the stock, 10 rate it Buy or Strong Buy, 4 rate it Hold, and 1 rate it Sell or Strong Sell. The consensus 12-month price target is $46, implying +137.7% from the current price of $19.
02What is the DBVT stock price target for 2026?
The Wall Street consensus price target for DBVT is $46 based on 15 analyst estimates. The high-end target is $51 (+161.7% from today), and the low-end target is $40 (+105.2%).
03Is DBV Technologies S.A. (DBVT) stock overvalued in 2026?
Forward earnings data for DBVT is not currently available. Review the valuation table above for trailing P/E, EV/EBITDA, and price-to-sales comparisons against market and sector benchmarks.
04What are the main risks for DBV Technologies S.A. (DBVT) stock in 2026?
The primary risks for DBVT in 2026 are: (1) Valuation de-rating — DBVT trades at -0. (2) Estimate execution — The next fiscal year requires Street estimates of $1M in revenue (115. (3) Capital return support — Part of the per-share support comes from capital returns, backed by -$151M in trailing free cash flow, a 0. Each factor has the potential to pressure earnings or compress the stock's valuation multiple.
05What is DBV Technologies S.A.'s revenue and earnings forecast?
Analyst consensus estimates DBVT will report consensus revenue of $1M (+115.0% year-over-year) and EPS of $-0.14 (+97.8% year-over-year) for the upcoming fiscal year. The following year, analysts project $18M in revenue.
06When does DBV Technologies S.A. (DBVT) report its next earnings?
A confirmed upcoming earnings date for DBVT is not yet available. Check the Earnings section above for the most recent quarterly report dates and forward estimates.
07How much free cash flow does DBV Technologies S.A. generate?
DBV Technologies S.A. (DBVT) had a free cash outflow of $151M in free cash flow over the trailing twelve months. DBVT returns capital to shareholders through and share repurchases ($0 TTM).